A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity
Jean Pierre Bikorimana, Nathanael A. Caveney, Nehme EL-Hachem, Gabrielle A. Mandl, John A. Capobianco, Daniela Stanga, Jamilah Abusarah, Mark A. Hancock, Roudy Farah, Marina P. Gonçalves, Darryl Falzarano, Mingmin Liao, Glenn Hamonic, Qiang Liu, Simon Beaudoin, Sebastien Talbot
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · vaccines and immunoinformatics approaches · Animal Virus Infections Studies
Main text
(iScience 28, 113314; September 19, 2025)
During copyediting, the production team mistakenly changed “A” to “An” in the title “A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.” This has now been updated online. The production team apologizes for this error.